CO5640072A2 - Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion - Google Patents
Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacionInfo
- Publication number
- CO5640072A2 CO5640072A2 CO05125195A CO05125195A CO5640072A2 CO 5640072 A2 CO5640072 A2 CO 5640072A2 CO 05125195 A CO05125195 A CO 05125195A CO 05125195 A CO05125195 A CO 05125195A CO 5640072 A2 CO5640072 A2 CO 5640072A2
- Authority
- CO
- Colombia
- Prior art keywords
- dosage form
- unit dosage
- atorvastatin
- per
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1.- Una forma farmacéutica unitaria que comprende (a) atorvastatina o una sal farmaceuticamente aceptable de los mismos, en la que dicha atorvastatina o una de sus sales farmacéuticamente aceptable, es una forma de atorvastatina que está, al menos, algo desordenada, o es una mezcla de formas cristalina y desordenada de atorvastatina, un excipiente o combinación de excipientes que contiene al menos aproximadamente 5% en peso, de un aditivo constituido por un agente alcalinizante, en donde dicha forma farmacéutica unitaria es preparada sin etapa de granulación, en la que la potencia de atorvastatina medida de dicha forma farmacéutica de administración, muestra una desviación típica relativa para la actividad de la atorvastatina por forma farmacéutica unitaria, no mayor que 7,8%, aproximadamente, cuando dicha forma farmacéutica unitaria se prepara a una velocidad mayor que 10.000 formas farmacéuticas unitarias por hora, por forma farmacéutica unitaria única, por hora, por máquina.2.- La forma farmacéutica unitaria según la reivindicación 2, en la que dicho excipiente o combinación de excipientes comprende aproximadamente más del 50% en peso, de un diluyente o de una combinación de diluyentes.3.- La forma farmacéutica unitaria según la reivindicación 6, en la que dicho diluyente es lactosa monohidratada, lactosa anhidra, celulosa microcristalina o cloruro de sodio.4.- La forma farmacéutica unitaria según la reivindicación 6, en la que dicha forma farmacéutica unitaria es un comprimido o una cápsula y contiene también al menos un fármaco activo además de la atorvastatina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47791803P | 2003-06-12 | 2003-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5640072A2 true CO5640072A2 (es) | 2006-05-31 |
Family
ID=33551781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05125195A CO5640072A2 (es) | 2003-06-12 | 2005-12-12 | Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion |
Country Status (23)
Country | Link |
---|---|
US (2) | US20050271717A1 (es) |
EP (2) | EP1635791B1 (es) |
JP (1) | JP2006527256A (es) |
KR (1) | KR20060028768A (es) |
CN (1) | CN100446757C (es) |
AR (1) | AR044775A1 (es) |
AT (1) | ATE399537T1 (es) |
AU (1) | AU2004246866A1 (es) |
BR (1) | BRPI0411079A (es) |
CA (1) | CA2465621A1 (es) |
CO (1) | CO5640072A2 (es) |
DE (1) | DE602004014765D1 (es) |
DK (1) | DK1635791T3 (es) |
ES (1) | ES2305775T3 (es) |
MX (1) | MXPA05013392A (es) |
NO (1) | NO20055185L (es) |
PL (1) | PL1635791T3 (es) |
PT (1) | PT1635791E (es) |
RU (1) | RU2314804C2 (es) |
SI (1) | SI1635791T1 (es) |
TW (1) | TW200509905A (es) |
WO (1) | WO2004110409A1 (es) |
ZA (1) | ZA200509906B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SI1937642T1 (sl) * | 2005-10-19 | 2015-01-30 | Teva Pharmaceutical Industries Ltd. | Kristali natrijevega lakvinimoda in postopek za njihovo pripravo |
EP1810667A1 (en) * | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
TWI400073B (zh) * | 2006-06-12 | 2013-07-01 | Teva Pharma | 穩定之拉癸利莫(laquinimod)製劑 |
US20080249141A1 (en) * | 2007-04-06 | 2008-10-09 | Palepu Nageswara R | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
DE102007052071A1 (de) * | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
RS53199B (en) | 2007-12-20 | 2014-06-30 | Teva Pharmaceutical Industries Ltd. | STABLE LAKVINIMOD PREPARATIONS |
WO2009116061A2 (en) * | 2008-01-10 | 2009-09-24 | Alkem Laboratories Ltd. | Stable oral pharmaceutical composition comprising atorvastatin |
GB0800788D0 (en) * | 2008-01-16 | 2008-02-27 | Glaxo Group Ltd | Niovel formulation |
CA2637977A1 (en) * | 2008-07-15 | 2010-01-15 | Pharmascience Inc. | Dosage form containing a statin |
BRPI0913518A2 (pt) * | 2008-09-03 | 2016-07-26 | Teva Pharma | composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune |
DK2458992T3 (en) * | 2009-07-30 | 2016-02-08 | Teva Pharma | Treatment of crohn's disease with laquinimod |
WO2011019375A1 (en) * | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
US9334266B2 (en) | 2009-09-04 | 2016-05-10 | The University Of Toledo | Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby |
KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
EA201491460A1 (ru) | 2012-02-03 | 2015-01-30 | Тева Фармасьютикал Индастриз Лтд. | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
KR20150091077A (ko) | 2012-11-07 | 2015-08-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드의 아민염 |
WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
TW201912157A (zh) | 2017-08-18 | 2019-04-01 | 美商艾伯維有限公司 | 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群及子宮腺肌症之固體醫藥調配物 |
AU2018317472A1 (en) | 2017-08-18 | 2020-03-05 | Abbvie Inc. | Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
US11980627B2 (en) * | 2019-06-14 | 2024-05-14 | Joshua O. Atiba | Triple pharmaceutical composition for proteinaceous infection |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
WO1994016693A1 (en) * | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
PL193479B1 (pl) * | 1995-07-17 | 2007-02-28 | Warner Lambert Co | Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
KR100447370B1 (ko) * | 1996-07-29 | 2004-09-08 | 워너-램버트 캄파니 엘엘씨 | 보호된 (s)-3,4-디히드록시부티르산 에스테르의 개선된 제조 방법 |
GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
HUP0100252A3 (en) * | 1997-12-19 | 2002-12-28 | Warner Lambert Exp Ltd Dun Lao | Process for the synthesis of 1,3-diols |
JP2002509103A (ja) * | 1998-01-20 | 2002-03-26 | アプライド・アナリティカル・インダストリーズ,インコーポレイテッド | 経口液体組成物 |
SI20109A (sl) | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
IN191236B (es) | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
SI1235799T1 (en) | 1999-11-17 | 2005-06-30 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
ES2372682T5 (es) | 2000-04-10 | 2014-10-30 | Teva Pharmaceutical Industries Ltd. | Composiciones farmacéuticas estables que contienen ácidos 7-sustituidos-3,5-dihidroxiheptanoicos o ácidos 7-sustituidos-3,5-dihidroxiheptenoicos |
IL155734A0 (en) | 2000-11-03 | 2003-11-23 | Teve Pharmaceutical Ind Ltd | Atorvastatin hemi-calcium form vii |
DK1341785T3 (da) | 2000-11-16 | 2009-01-26 | Teva Pharma | Hydrolyse af R (R*,R*)-2-(4-fluorphenyl)-beta.delta-dihydroxy-5 (1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrol-1-heptansyrester med calciumhydroxid |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
MXPA03005879A (es) | 2000-12-27 | 2003-09-10 | Ciba Sc Holding Ag | Formas cristalinas de atorvastatina. |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
EP1241110A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Dispensing unit for oxygen-sensitive drugs |
EP1243524A3 (en) | 2001-03-16 | 2004-04-07 | Pfizer Products Inc. | Pharmaceutical kit for oxygen-sensitive drugs |
IN190564B (es) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
RS100003A (en) * | 2001-06-29 | 2007-02-05 | Warner-Lambert Company, | Crystalline forms of /r-(r*,r*)-2-(4- fluorphenyl)-beta,delta -dihydroxy-5(1- methylethyl)-phenyl-4-/phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CZ2004126A3 (cs) | 2001-07-30 | 2004-12-15 | Dr. Reddy's Laboratories Limited | Krystalické formy VI. A VII. vápenaté soli atorvastatinu |
EP1414496B1 (en) * | 2001-08-07 | 2010-10-20 | Galephar M/F | Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride |
UA77990C2 (en) | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
AP2004003112A0 (en) * | 2002-02-14 | 2004-09-30 | Ranbaxy Lab Ltd | Formulations of atorvastatin stabilised with alkali metal additions |
DE03713610T1 (de) | 2002-02-15 | 2005-10-20 | Teva Pharma | Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium |
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
EP1562583A1 (en) | 2002-09-03 | 2005-08-17 | Morepen Laboratories Ltd. | Atorvastatin calcium form vi or hydrates thereof |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
-
2004
- 2004-04-20 US US10/828,419 patent/US20050271717A1/en not_active Abandoned
- 2004-04-29 CA CA002465621A patent/CA2465621A1/en not_active Abandoned
- 2004-06-01 MX MXPA05013392A patent/MXPA05013392A/es unknown
- 2004-06-01 EP EP04735619A patent/EP1635791B1/en not_active Revoked
- 2004-06-01 RU RU2005138496/15A patent/RU2314804C2/ru not_active IP Right Cessation
- 2004-06-01 BR BRPI0411079-0A patent/BRPI0411079A/pt not_active IP Right Cessation
- 2004-06-01 AU AU2004246866A patent/AU2004246866A1/en not_active Abandoned
- 2004-06-01 EP EP08153178A patent/EP1977738A1/en not_active Withdrawn
- 2004-06-01 PT PT04735619T patent/PT1635791E/pt unknown
- 2004-06-01 CN CNB2004800143122A patent/CN100446757C/zh not_active Expired - Fee Related
- 2004-06-01 KR KR1020057023838A patent/KR20060028768A/ko active IP Right Grant
- 2004-06-01 DE DE602004014765T patent/DE602004014765D1/de not_active Revoked
- 2004-06-01 JP JP2006516504A patent/JP2006527256A/ja active Pending
- 2004-06-01 SI SI200430802T patent/SI1635791T1/sl unknown
- 2004-06-01 AT AT04735619T patent/ATE399537T1/de not_active IP Right Cessation
- 2004-06-01 ES ES04735619T patent/ES2305775T3/es not_active Expired - Lifetime
- 2004-06-01 WO PCT/IB2004/001845 patent/WO2004110409A1/en active IP Right Grant
- 2004-06-01 DK DK04735619T patent/DK1635791T3/da active
- 2004-06-01 PL PL04735619T patent/PL1635791T3/pl unknown
- 2004-06-10 AR ARP040102010A patent/AR044775A1/es unknown
- 2004-06-11 TW TW093116996A patent/TW200509905A/zh unknown
-
2005
- 2005-11-04 NO NO20055185A patent/NO20055185L/no not_active Application Discontinuation
- 2005-12-06 ZA ZA200509906A patent/ZA200509906B/en unknown
- 2005-12-12 CO CO05125195A patent/CO5640072A2/es not_active Application Discontinuation
-
2009
- 2009-05-08 US US12/424,972 patent/US20090226510A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2004246866A1 (en) | 2004-12-23 |
TW200509905A (en) | 2005-03-16 |
RU2005138496A (ru) | 2006-04-27 |
ZA200509906B (en) | 2007-01-31 |
NO20055185D0 (no) | 2005-11-04 |
US20050271717A1 (en) | 2005-12-08 |
MXPA05013392A (es) | 2006-03-09 |
EP1635791A1 (en) | 2006-03-22 |
WO2004110409A1 (en) | 2004-12-23 |
ATE399537T1 (de) | 2008-07-15 |
BRPI0411079A (pt) | 2006-07-25 |
DK1635791T3 (da) | 2008-08-25 |
CN100446757C (zh) | 2008-12-31 |
ES2305775T3 (es) | 2008-11-01 |
DE602004014765D1 (de) | 2008-08-14 |
PL1635791T3 (pl) | 2008-11-28 |
KR20060028768A (ko) | 2006-04-03 |
RU2314804C2 (ru) | 2008-01-20 |
EP1635791B1 (en) | 2008-07-02 |
SI1635791T1 (sl) | 2008-10-31 |
JP2006527256A (ja) | 2006-11-30 |
EP1977738A1 (en) | 2008-10-08 |
US20090226510A1 (en) | 2009-09-10 |
NO20055185L (no) | 2006-03-09 |
PT1635791E (pt) | 2008-09-10 |
CA2465621A1 (en) | 2004-12-12 |
CN1794978A (zh) | 2006-06-28 |
AR044775A1 (es) | 2005-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5640072A2 (es) | Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion | |
ES2290457T3 (es) | Tableta con alta carga de farmaco. | |
ES2326167T3 (es) | Comprimidos dispersables de deferasirox. | |
AR111572A2 (es) | Formas farmacéuticas que contienen vardenafilo | |
UY27553A1 (es) | Formulaciones farmacéuticas de 5,7,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2/11),3,5,7,9-pentaeno | |
CO5170471A1 (es) | Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio | |
DE60032749D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
CO4480020A1 (es) | Formulaciones farmaceuticas | |
RU2016122609A (ru) | Составы соединений азаиндола | |
JP2006516570A5 (es) | ||
HUP0101246A2 (hu) | Meloxicam új galenusi formulációi orális alkalmazásra és eljárás az előállításukra | |
SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
MX9300664A (es) | Formas de dosis farmaceuticas que contienen liberacion prolongada de ingrediente activo. | |
CO5390076A1 (es) | Composiciones farmaceuticas | |
WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
DE50203456D1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
CO5650230A2 (es) | Composiciones estables de atorvastatina preparadas con granulacion en humedo | |
UA85359C2 (ru) | Таблетка, содержащая гранулированный материал с kmd-3213 | |
SE9901573D0 (sv) | New compounds | |
HUP0301390A2 (hu) | Valzartánt tartalmazó orális gyógyászati készítmény | |
AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
JP6088429B2 (ja) | 関節リウマチなどの自己免疫疾患の治療の改善方法 | |
ES2197676T3 (es) | Composiciones farmaceuticas que comprenden ibuprofeno y domperidona. | |
HUP0400127A2 (hu) | Paracetamolt tartalmazó lenyelhető tabletta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |